Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
ACELYRIN Price Target Cut to $6.00/Share From $13.00 by Morgan Stanley
Acelyrin Analyst Ratings
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6
ACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash Runway
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Acelyrin Analyst Ratings
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Piper Sandler Keeps Their Buy Rating on ACELYRIN, INC. (SLRN)
ACELYRIN, INC. Maintains Hold Rating Amidst Mixed Clinical Results and Competitive Market Challenges
Buy Rating Affirmed: Strategic Focus and Promising Pipeline of ACELYRIN, INC.
Acelyrin Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Acelyrin Analyst Ratings
Acelyrin Analyst Ratings
Buy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising Pipeline
Acelyrin Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)
No Data